EcoR1 Capital
Facts
- HQ
- San Francisco, CA
- Sectors
- Venture Capital
Recent coverage
Front-page news, podcasts and videos about EcoR1 Capital
Notch Therapeutics raises $85M Series A (total $91M) to fund stem cell–derived T cell therapies and open Seattle lab
Notch Therapeutics raised an $85 million Series A, bringing total funding to $91 million, to advance stem cell–derived T cell immunotherapies and expand with a new Seattle research lab. The 2018-founded biotech plans to grow from 35 to about 100 employees by end of 2022 and is collaborating with Allogene Therapeutics on treatments for blood cancers.
Silverback Therapeutics raises $85M Series C — six months after $78.5M — to fund SBT6050 Phase 1 work; total VC $210M
Seattle biotech Silverback Therapeutics raised an $85 million Series C just six months after a $78.5 million round to advance its ImmunoTAC platform and lead candidate SBT6050 in a Phase 1 study; total VC funding is $210 million. The company named Valerie Odegard president and chief scientific officer, Naomi Hunder chief medical officer, and appointed Laura Shawver as CEO in April.
